TACE/ADAM-17 and MMP inhibitor. Blocks shedding of TNF from cell membranes. Reduces pain-associated behavior in mice with a constructive mononeuropathy.
|Storage||Store at -20°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solubility||Soluble to 10 mg/ml in DMSO and to 10 mg/ml in PBS|
References are publications that support the biological activity of the product.
Sommer et al (1997) A metalloprotease-inhibitor reduces pain associated behavior in mice with experimental neuropathy. Neurosci. Lett. 237 45 PMID: 9406876
Mohler et al (1994) Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 370 218 PMID: 8028669
If you know of a relevant reference for TAPI 1, please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: TAPI 1, TAPI 1 supplier, TAPI1, ADAM17, metalloproteases, MMPs, metalloproteinases, inhibits, inhibitors, adams, TNFa, TNFα, converting, enzyme, TACE, ADAMs, Matrix, Metalloprotease, 6162, Tocris Bioscience
Citations for TAPI 1
Citations are publications that use Tocris products.
Currently there are no citations for TAPI 1. Do you know of a great paper that uses TAPI 1 from Tocris? Please let us know.
Reviews for TAPI 1
There are currently no reviews for this product. Be the first to review TAPI 1 and earn rewards!
Have you used TAPI 1?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Alzheimer's disease (AD) is a degenerative brain disease and the most common cause of dementia, affecting approximately 47 million people worldwide. Updated in 2015, this poster summarizes the structural and functional changes observed in the progression of this neurodegenerative disease, as well as classic AD drug targets.